secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moderna, Inc. (MRNA)
CIK:        0001682852
Form:       8-K
Filed at:   2023-10-16T23:59:59+00:00
Accession:  0001682852-23-000033
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Moderna reaffirms FY2023 COVID-19 vaccine revenue guidance of $6-8B; provides scenario-based range
--------------------------------------------------------------------------------

- Full-year 2023 COVID-19 vaccine revenue guidance unchanged at $6B-$8B.
- If U.S. market is ~50M doses, expects to be in bottom half of range.
- If U.S. market is ~100M doses, expects to be in top half of range.
- Too early to project; better visibility after October vaccination trends.
- Will provide an update at the November 2 earnings call.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1682852/000168285223000033/0001682852-23-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1682852/000168285223000033/mrna-20231016.htm
  HTML page:      https://secwatch.observer/filing/0001682852-23-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer